Found 7 articles
12/16/2020A roundup of life sciences companies raking in the cash.
San Diego-based Locanabio secured $100 million in a Series B financing round that will be used to advance the company’s portfolio of novel RNA-targeted gene therapies for neurodegenerative, neuromuscular and retinal diseases.
Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases
Financing led by Vida Ventures LLC with participation from RA Capital Management, Invus, Acuta Capital Partners, an investment fund associated with SVB Leerink, ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures and GV. Funding supports pre-clinical and clinical development of proprietary RNA-targeting systems delivered via gene therapy for treating genetic diseases such as Huntington's disease, myotonic dystrophy type 1, genetic ALS, and retinal disease.
Locanabio, Inc., a leader in engineering RNA-binding proteins that can target disease-causing mRNA using gene therapy delivery, today announced that Jim Burns , Ph.D., chief executive officer at the company, and Dimitrios G. Zisoulis, Ph.D., head of RNA biology and drug discovery, will participate in the following upcoming conferences:
RNA-binding proteins are emerging as the next generation of molecular medicine.
Treatment with RNA-Targeting Gene Therapy Reverses Molecular and Functional Features of Myotonic Dystrophy Type 1 in Mice
Locanabio, Inc., a leader in RNA-targeted gene therapy, today announced that results from a preclinical study of the company's therapeutic systems for the potential treatment of myotonic dystrophy type 1 (DM1) were published in Nature Biomedical Engineering.
7/22/2020Locanabio combines gene therapy with RNA modification for a novel, highly flexible platform that can modify, replace or eliminate dysfunctional RNA. Gene therapy and RNA modification have each been used before. It’s the combination that makes it unique.